ArticleJournal for immunotherapy of cancer2021

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.

Craig L Slingluff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.